Pharmaceutical Companies Team Up to Develop Acromegaly Treatment

December 8, 2020

Two pharmaceutical companies will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Growth Issues Product / Technology

←Third Rock from the Sun: Endocrinology and Climate Change

In the Mix: Combination Therapy for Hypothyroidism Gets Another Look→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today